表阿霉素市场基于(关键地区、市场参与者、规模和份额)- 到 2031 年的预测

  • Report Code : TIPRE00008627
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 163
Buy Now

表柔比星市场预计将从 2021 年的 1.9166 亿美元增至 2028 年的 2.4399 亿美元;预计2022年至2028年复合年增长率为3.60%。

表柔比星是一种蒽环类药物,于1980年发表第一个临床试验。该药物旨在由于疗效和质量更好,比阿霉素更受青睐。它用于化疗目的以治疗各种癌症。该药物单独或联合使用,主要用于治疗乳腺癌、卵巢癌、肝癌、膀胱癌等。该产品的作用是减缓或阻止体内癌细胞的生长。联合疗法包括氟尿嘧啶、盐酸表柔比星和环磷酰胺 (FEC),其中该产品与氟尿嘧啶和环磷酰胺一起服用。与单一疗法相比,表柔比星的辅助疗法似乎毒性较小。它由辉瑞公司在美国以商品名 Ellence 销售,在其他地方以 Pharmorubicin 或 Epirubicin Ebewe 销售。 2007年8月,该产品失去专利并成为通用名。由于其副作用,该产品在癌症治疗中的应用范围有限。常见的副作用是心脏、骨髓和血液。

表柔比星(EPI)成功融入固液纳米颗粒制剂中,生产出稳定的可吸入雾化剂用于治疗肺癌的悬浮液。

战略洞察

表阿霉素市场根据剂量、应用、分销渠道和地理位置进行细分。按地域划分,市场大致分为北美、欧洲、亚太地区、中东和中东地区。非洲、南美和非洲中美洲。该报告提供了对市场的见解和深入分析,强调市场趋势和市场动态等参数以及全球领先市场参与者的竞争分析。

表阿霉素市场利润丰厚的地区

市场洞察

癌症患病率上升

表阿霉素是一种抗癌药物,属于蒽环类药物,用于治疗乳腺癌、胃癌等。它通过攻击手术或放射治疗去除大部分肿瘤细胞后剩余的肿瘤细胞来降低复发风险。

根据美国癌症协会的数据,全球癌症负担预计在 2021 年将增加到 19,300 例新病例,到 2020 年将增加 10,000 例死亡。根据美国国家癌症研究所(美国)的数据,发病率和癌症发病率的增加癌症的流行对全球社会产生重大影响。据该机构统计,美国有近1800人被诊断患有癌症,2020年约有606,520人罹患该病。根据国际癌症研究机构的数据,2020年乳腺癌发病率为2,261,419人约占全球癌症病例总数的 11.7%。此外,2020 年该疾病导致 684,996 人死亡。因此,与癌症相关的高发病率预计将显着影响市场增长。据美国疾病控制与预防中心 (CDC) 统计,美国每年约有 24,500 名男性和 10,000 名女性罹患肝癌,约 18,600 名男性和 9,000 名女性死于该病。几十年来,美国人患肝癌的比例一直在上升。肝癌在世界其他地区比在美国更常见。因此,癌症病例患病率的上升正在推动表柔比星市场的发展。

中东和中东地区的医疗保健行业非洲地区仍在发展中;因此,他们面临着 COVID-19 大流行带来的最大挑战。卫生当局担心,试图抗击 COVID-19 会间接导致包括癌症患者在内的病人死亡人数增加。由于许多医院的资源和人员有限,医疗保健专业人员限制了患者的预约,因此低成本地区的病人死亡人数预计会增加。

但是,2021 年启动新冠疫苗接种计划,多个国家控制了局势。这些控制传播的努力最终将恢复和恢复大流行后的情况。

促进表阿霉素市场增长的发展示例如下:< /h3>
  • 2018年4月,Hikma Pharmaceuticals PLC(Hikma Group)宣布其全资美国子公司West-Ward Pharmaceuticals Corp.(West-Ward),已推出盐酸表柔比星注射液,USP 50mg/25mL 和 200mg/100mL 小瓶装,仿制药相当于 Ellence。 West-Ward 的盐酸表柔比星注射液 (USP) 是原发性乳腺癌切除术后有腋窝淋巴结肿瘤受累证据的患者辅助治疗的组成部分。
< h3>表阿霉素市场-应用洞察

根据应用,表阿霉素市场分为乳腺癌、肝癌、膀胱癌和其他癌症。乳腺癌细分市场在 2021 年占据最大的市场份额。预计乳腺癌细分市场在预测期内将实现最高的复合年增长率,并且预计同一细分市场在预测期内将实现最高的复合年增长率。 20世纪70年代,表柔比星作为治疗转移性乳腺癌的药物推出,目前是治疗乳腺癌最活跃的单一药物之一。可以在乳腺癌的早期阶段使用药物来减少乳腺癌复发的机会。它被广泛用作手术和淋巴结转移患者的辅助治疗。因此,在大多数情况下,该药物通常与其他药物一起开出。在某些情况下,它可以用作阿霉素(阿霉素)的替代品,因为它对心脏的损害可能比阿霉素小。该药物通过静脉注射,通常每三周注射一次或每 28 天注射两次,共 6 个周期。该药物由辉瑞公司和山德士(诺华公司的一个部门)等公司在市场上销售。癌症治疗不断发展;因此,各种公司正在市场上推出产品。例如,2018年4月,Hikma Pharmaceuticals PLC推出了盐酸表阿霉素注射液(USP),有50mg/25mL和200mg/100mL小瓶等多种规格。该产品为通用版本,相当于Ellence。因此,市场上的产品可用性和产品发布可能会在预测期内增强市场的增长。

表柔比星市场,按应用划分 - 2021年和2028年

表阿霉素市场-剂量洞察

根据剂量,全球表阿霉素市场细分为10mg /瓶、50mg/瓶、100mg/瓶和200mg/瓶。 2021 年,50 毫克/瓶细分市场占据最大市场份额;然而,预计 100 毫克/瓶细分市场在预测期内复合年增长率最高。表柔比星50毫克注射液是一种抗癌剂,用作治疗乳腺癌的辅助药物。它具有起泡性,应在合格医生的监督下注射到静脉中。 10毫克表柔比星的作用平均持续3至4天。表阿霉素市场的市场参与者提供不同剂量的表阿霉素。例如,辉瑞提供 10 毫克和 50 毫克剂量的盐酸表阿霉素。

表阿霉素市场 - 分销渠道洞察

基于分销渠道,全球表阿霉素市场分为医院药房、零售药房和在线药房。 2021 年,医院药房细分市场占据最大市场份额。预计该细分市场在预测期内的复合年增长率最高,为 4.0%。医院药房是医疗机构患者护理的一个组成部分。医院药学是一个致力于持续维护和加强患者药学护理和药物管理以达到医院环境中最高标准的领域。医院药房是医院采购、储存、配制、分发、制造、测试、包装和分发药品的主要区域之一。控制医院和其他医疗机构的药品使用是医院药房的主要职责。药品的选择、处方、采购、交付、管理和审查都是旨在改善患者治疗效果的目标。

表阿霉素市场 –按地区划分

按地理位置,表柔比星市场分为北美(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、意大利、西班牙和欧洲其他地区)、亚太地区(中国、日本、印度、澳大利亚、韩国和亚太地区其他地区)、中东和美国非洲(阿联酋、沙特阿拉伯、非洲以及中东和非洲其他地区)以及南美和非洲中美洲(巴西、阿根廷以及南美洲和中美洲其他地区)。

表阿霉素市场 - 公司简介

表阿霉素市场主要由 Pfizer, Inc. 等公司组成;梯瓦制药工业有限公司; Salius Pharma Pvt Ltd;阿海珐制药公司;迈兰公司; Hikma 制药公司;费森尤斯·卡比股份公司;和 Miracalus Pharma Pvt.有限公司

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is Epirubicin?

Epirubicin HCl is a class of drugs termed anthracyclines and is primarily used to treat breast cancers after surgical resection. Anthracyclines are an antibiotic isolated from the gram-positive bacteria Streptomyces. They are commonly used as chemotherapy agents and exert their antineoplastic effects by targeting the replication of DNA. Epirubicin HCl is often preferred over anthracycline doxorubicin as it has been shown to have fewer side effects. Epirubicin HCl became FDA-approved as adjuvant therapy for treating axillary node-positive breast cancers following resection under the trade name Ellence in 1999. It is currently manufactured through large-scale semi-synthetic methods using daunorubicin as starting material for its preparation.

What are the driving factors for the epirubicin market across the globe?

Factors such as rising prevalence of cancer and increasing awareness regarding cancer are propelling the market growth.

What are the restraining factors for the epirubicin market?

The elevated risk of adverse effects due to epirubicin is hampering the market's growth.

Who are the major players in market the epirubicin market?

The epirubicin market majorly consists of the players such as Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharamceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd.

Which segment is dominating the epirubicin market?

Based on dosage, the global epirubicin market is segmented into 10mg/Vial, 50mg/Vial, 100mg/Vial, and 200mg/Vial. The 50mg/Vial segment held the largest share of the market in 2021, however, 100mg/Vial segment is anticipated to register the highest CAGR in the market during the forecast period.

Which region is dominating the epirubicin market?

The global epirubicin market on region, is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and the South & Central America. North America held the largest market share for epirubicin in 2021. The United States held the largest market in North America for epirubicin, and the market is expected to grow due to rising prevalence of cancer and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the epirubicin market.

The List of Companies - Epirubicin Market

  1. Pfizer, Inc.
  2. Teva Pharmaceutical Industries Ltd.
  3. Salius Pharma Pvt Ltd
  4. Areva Pharmaceuticals Mylan N. V.
  5. Hikma Pharmaceuticals PLC
  6. Fresenius Kabi AG
  7. Miracalus Pharma Pvt. Ltd.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports